Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Quarterly Report · 10-Q

Eledon Pharmaceuticals, Inc.

ELDNNASDAQEQUITYCurrent

Quarterly Report

Filed Nov 12, 2026Accepted Nov 12, 2026, 4:30 PM ESTCIK 1404281Accession 0001193125-26-458564
Share

Company context

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 12, 2026
  2. S-8 filingSep 4, 2026
  3. 10-Q filingAug 13, 2026
  4. Results of Operations and Financial ConditionAug 13, 2026
  5. SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Eledon Pharmaceuticals, Inc.Jul 31, 2026

Registered securities in this filing

ELEDON PHARMACEUTICALS, INC. · 10-Q · Filed 2026-11-12

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.001 par value

Symbol
ELDN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_39ab0212-964b-49ee-a99f-2a6690951e69

Dimensions: Not supplied

Accession 000119312526458564 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.